Velan Capital Investment Management LP Purchases New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Velan Capital Investment Management LP acquired a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 28,685 shares of the specialty pharmaceutical company's stock, valued at approximately $822,000. Collegium Pharmaceutical makes up about 0.7% of Velan Capital Investment Management LP's portfolio, making the stock its 17th biggest position. Velan Capital Investment Management LP owned 0.09% of Collegium Pharmaceutical at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after purchasing an additional 289,335 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Collegium Pharmaceutical by 0.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after buying an additional 5,480 shares during the period. Northern Trust Corp boosted its stake in shares of Collegium Pharmaceutical by 5.6% in the 4th quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock worth $11,035,000 after buying an additional 20,490 shares during the last quarter. Royce & Associates LP grew its holdings in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock worth $9,728,000 after acquiring an additional 33,674 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in shares of Collegium Pharmaceutical by 319.4% in the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after acquiring an additional 221,903 shares during the period.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at approximately $3,732,630. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares in the company, valued at approximately $4,928,070. This represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,693 shares of company stock valued at $2,334,994. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $30.23 on Monday. The company has a market capitalization of $971.35 million, a P/E ratio of 13.03 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The firm's 50 day simple moving average is $28.12 and its two-hundred day simple moving average is $29.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company's quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.45 EPS. Research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Needham & Company LLC restated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.